Increasing use of peptides in pharmaceutical drugs drives the global peptide synthesis market

Peptides are highly active and highly specific drug substances. Due to the diversity of their biological functions, they are used in an extensive range of therapeutic areas. Also, they are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity.

Oncology, diabetes, and obesity are three prominent therapeutic areas in which peptides generate billions of dollars in revenues. As a drug modality, peptides and peptidomimetics occupy the interface between small molecules and larger biological drugs with the potential to have the specificity of antibodies and the bioavailability of small molecules.

Moreover, peptides provide researchers with viable options for discovery, optimization, and manufacture, as they can be synthesized chemically or expressed by recombinant systems. As a result of these advantages, pharmaceutical companies are increasingly focusing on the development of peptide-based drugs.

Global Revenue Surge:

The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

Major Growth Boosters:

Growth in this market is driven by the increasing use of peptides in pharmaceutical drugs, rise in research activities and availability of funding for R&D, and the development of advanced technological peptide synthesizers.

Major Market Developments:

# In 2018, CEM Corporation launched the Liberty PRIME, automated microwave peptide synthesizer.
# In 2017, Merck acquired Grzybowski Scientific Inventions (GSI) (US). This acquisition helped the company to expand its chemical synthesis portfolio.
# In 2015, Merck acquired Sigma-Aldrich Corporation (US). This acquisition strengthened Merck’s Life Science segment. Sigma-Aldrich’s SAFC Commercial business is now a part of Merck’s Life Science segment.

Pharmaceutical & biotechnological companies are expected to dominate the peptide synthesis market in 2017

Based on end users, the peptide synthesis market is segmented into pharmaceutical & biotechnological companies, contract development and manufacturing organizations, and academic and research institutes. In 2017, pharmaceutical & biotechnological companies accounted for the largest market share due to increasing number of research projects in genomics, molecular biology, and related areas; growing application areas of peptides in drug discovery, therapeutics, and research; and substantial R&D investments.

APAC is expected to grow at the highest CAGR during the forecast period.

Global peptide synthesis market has been studied for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. APAC is expected to grow at the highest CAGR in the peptide synthesis market, primarily due to the increasing investments by pharmaceutical and biotechnology companies and rising R&D activities in the region.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

Global Leaders:

The prominent players in the peptide synthesis market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGaA (Germany) and New England Peptide, Inc (US). Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the peptide synthesis market.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]